Related Experiment Video
Updated: Jan 23, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Treatment with Statins Does Not Revert Trained Immunity in Patients with Familial Hypercholesterolemia
Siroon Bekkering1, Lotte C A Stiekema2, Sophie Bernelot Moens2
1Department of Internal Medicine, and Radboud Institute for Molecular Life Sciences (RIMLS), Radboud University Medical Center, Nijmegen 6525GA, the Netherlands; Department of Vascular Medicine, Amsterdam University Medical Centres, University of Amsterdam, 1105AZ Amsterdam, the Netherlands.
Insights
Individuals with high LDL-cholesterol face cardiovascular risks. Familial hypercholesterolemia patients show trained immunity, which statins do not resolve, indicating persistent inflammation.
Area of Science:
- Immunology
- Cardiovascular Science
- Metabolic Disorders
Background:
- Elevated low-density lipoprotein (LDL)-cholesterol is a major risk factor for cardiovascular disease.
- Current lipid-lowering strategies, including statins, reduce LDL-C but residual cardiovascular risk persists.
- Familial hypercholesterolemia (FH) is a genetic disorder characterized by extremely high LDL-C levels.
Discussion:
- Monocytes from FH patients exhibit a trained immunity phenotype, characterized by enhanced inflammatory responses.
- This pro-inflammatory phenotype is linked to increased cardiovascular risk.
- Lipid-lowering therapy with statins did not revert the trained immunity phenotype in FH monocytes.
Key Insights:
- FH monocytes possess a persistent, trained immunity phenotype.
- Statins, despite lowering LDL-C, do not reverse this pro-inflammatory cellular state.
- Trained immunity may contribute to residual cardiovascular risk in FH patients.
Outlook:
- Investigating novel therapeutic targets beyond LDL-C reduction is crucial.
- Exploring interventions to modulate trained immunity in FH patients may reduce cardiovascular events.
- Further research is needed to understand the long-term implications of trained immunity in metabolic diseases.
Abstract:
Individuals with elevated LDL-cholesterol levels have an increased risk for cardiovascular disease. Despite lipid lowering strategies, however, a significant cardiovascular risk remains. Bekkering et al. show that monocytes from patients with familial hypercholesterolemia have a trained immunity phenotype and that lipid lowering with statins does not revert this pro-inflammatory phenotype.
More Related Videos
06:00A Rehabilitation Program of Exoskeleton-assisted Body Weight-Supported Treadmill Training with Non-immersive Virtual Reality for Stroke Patients
Published on: May 16, 2025
04:22Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
Related Concept Videos
Protein Families
Protein Families
Gene Families
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
Gene Families
Family Therapy
Strategic Family Therapy
Strategic family therapy emphasizes resolving communication barriers and improving problem-solving abilities...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents